Follow
Jing Wang
Jing Wang
Professor of Bioinformatics, University of Texas M.D.Anderson Cancer Center
Verified email at mdanderson.org
Title
Cited by
Cited by
Year
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
41842018
Comprehensive molecular profiling of lung adenocarcinoma.
CGAR Network
3711*2014
Comprehensive genomic characterization of head and neck squamous cell carcinomas
TCGA Network
Nature, 2015
31292015
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
23432018
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
20802018
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1
N Agrawal, MJ Frederick, CR Pickering, C Bettegowda, K Chang, RJ Li, ...
Science 333 (6046), 1154-1157, 2011
19822011
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ...
Cell 173 (2), 291-304. e6, 2018
19382018
Comprehensive and integrative genomic characterization of hepatocellular carcinoma
A Ally, M Balasundaram, R Carlsen, E Chuah, A Clarke, N Dhalla, RA Holt, ...
Cell 169 (7), 1327-1341. e23, 2017
17902017
Machine learning identifies stemness features associated with oncogenic dedifferentiation
TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ...
Cell 173 (2), 338-354. e15, 2018
14822018
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Skoulidis F, et al
Cancer Discov, 2018
12062018
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang ...
Cell, 2017
11192017
Integrated genomic and molecular characterization of cervical cancer.
CGAR Network
Nature, 2017
1034*2017
An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor …
LA Byers, L Diao, J Wang, P Saintigny, L Girard, M Peyton, L Shen, Y Fan, ...
Clinical cancer research 19 (1), 279-290, 2013
9912013
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.
Nat Commun, 2014
889*2014
Genomic and functional approaches to understanding cancer aneuploidy
AM Taylor, J Shih, G Ha, GF Gao, X Zhang, AC Berger, SE Schumacher, ...
Cancer cell 33 (4), 676-689. e3, 2018
8142018
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, Izzo, ...
Cancer Discovery 5, 860-77, 2015
7592015
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas
CGAR Network
Cell, 2017
7552017
Pathogenic germline variants in 10,389 adult cancers
K Huang, RJ Mashl, Y Wu, DI Ritter, J Wang, C Oh, M Paczkowska, ...
Cell 173 (2), 355-370. e14, 2018
6872018
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines
DL Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess ...
Cell Syst, 2018
6272018
Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer
Sen T, Rodriguez BL, Chen L, Della Corte C, Morikawa N, Fujimoto J, Cristea ...
Cancer Discovery, 2019
6072019
The system can't perform the operation now. Try again later.
Articles 1–20